747 Protein Engineering III: Therapeutics

Thursday, November 12, 2015: 3:15 PM - 5:45 PM
151A/B (Salt Palace Convention Center)

Description:
This session will focus on protein engineering for therapeutic applications, with an emphasis on engineering peptides, antibodies, and other proteins with clinical relevance. Submissions with a broad range of applications, including cell targeting, imaging, therapeutics, and immunology, are encouraged.

Sponsor:
Bioengineering
Chair:
Amy J. Karlsson Email: ajkarl@umd.edu
Co-Chair:
Jeffrey Rice Email: jrice@tntech.edu
- indicates paper has an Extended Abstract file available on CD.


File available
3:15 PM
(747a) Engineered Therapeutic and Diagnostic Proteins Targeting Tumor Biomarker Mesothelin
Allison Sirois, Katia George and Sarah J. Moore


3:35 PM
(747b) Covert Cancer Therapeutics: Engineering T Cells to Interrogate Intracellular Tumor Antigens
Patrick Ho and Yvonne Chen


3:55 PM
(747c) Protease-Activatable Viruses for Cardiovascular Disease Therapy
Michelle L. Ho, Momona Yamagami, Michael Lam, Veronica Gough and Junghae Suh


4:15 PM
(747d) Targeted Enzyme Prodrug Therapy for Prostate Cancer – a Comparative Study of L-Methioninase, Purine Nucleoside Phosphorylase, and Cytosine Deaminase
Katrin Guillen, John Krais, Brent Van Rite, Carla Kurkjian and Roger G. Harrison


4:35 PM
(747e) DNA Aptamer Switch for Enzymatic Prodrug Activation Against Cancer
Rebecca P. Chen and Wilfred Chen


4:55 PM
(747f) Generation of Protease-Inhibiting Monoclonal Antibodies By Novel Paratope Design
Dong Hyun Nam, Carlos Rodriguez, Tyler Lopez and Ge Xin


5:15 PM
(747g) Cell-Free Protein Synthesis: A Dynamic Platform for Rapid Screening and Production of Cytotoxic Cancer Biotherapeutics
S.M. Amin Salehi, Mark T. Smith, Anthony M. Bennett and Bradley C. Bundy
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division
<< Previous Session | Next Session >>